Stratistics MRC에 따르면 세계의 우로키나제 시장은 2025년에 20억 8,000만 달러를 차지하고 예측 기간 중 CAGR은 7.7%로 확대되어 2032년에는 35억 달러에 이를 전망입니다.
우로키나제는 혈전 용해효소이며, 체내의 혈전을 용해하기 위해 의료용으로 사용됩니다. 주로 폐색전증, 심부정맥혈전증, 카테터 폐색 등의 치료에 사용됩니다.
영국 심장재단(British Heart Foundation)의 2024년 기사에 따르면 영국에서는 760만 명이 심장 및 순환기계 질환으로 생활하고 있습니다.
혈전성 질환의 유병률 상승
혈전성 질환의 이환율 증가는 혈전 용해 치료의 필요성이 증가함에 따라 우로키나제 시장을 촉진하고 있습니다. 이러한 질병의 세계 유병률이 특히 노화된 사람들 사이에서 상승함에 따라 효과적인 혈전 용해 치료에 대한 수요가 증가하고 있습니다.
높은 치료비
고액의 치료비는 특히 중저소득지역에서 환자와 의료 제공자의 접근을 제한함으로써 우로키나제 시장의 성장을 현저하게 저해하고 있습니다. 또한, 고가의 비용은 건강 예산을 압박하고, 보험 적용을 저해하고, 광범위한 임상 사용을 제한하기 때문에 궁극적으로 시장의 확대를 늦추고, 혈전 용해 요법의 기술 혁신을 저해합니다.
약물전달의 기술적 진보
약물 전달 시스템의 기술 발전은 치료 효과와 정확성을 향상시켜 우로키나제 시장에 큰 영향을 미칩니다. 이러한 진보는 특정 부위를 표적으로 하는 약물의 능력을 향상시키고 혈전과 심장 발작과 같은 질병의 치료를 최적화합니다.
출혈 합병증의 위험
출혈성 합병증의 위험은 우로키나제 시장의 성장을 현저하게 저해합니다. 이 안전성으로 인해 헬스케어 제공업체들 사이에서 우로키나제의 보급에는 한계가 있으며, 신중한 처방이 요구되고 있습니다. 또한, 규제상의 제한, 보다 안전한 대체약의 이용 가능성이 시장의 확대를 더욱 억제해, 수요와 시장 전체의 퍼포먼스에 부정적인 영향을 주고 있습니다.
COVID-19의 영향
COVID-19의 대유행으로 인해 우로키나제 시장은 대기 수술 지연, 입원 감소, 공급망 중단 등의 영향을 받아 크게 혼란스러웠습니다. 그러나 의료 시스템이 안정되고 수술이 재개되자 시장이 회복되기 시작했습니다.
예측 기간 동안 우로키나제 용액 부문이 최대가 될 것으로 예상
우로키나제 용액 부문은 예측 기간 동안 최대 시장 점유율을 차지할 것으로 예측됩니다.
심부정맥 혈전증 부문은 예측 기간 동안 가장 높은 CAGR이 예상됩니다.
예측 기간 동안 심부정맥 혈전증 분야는 혈전성 질환의 이환율의 상승과 조기 진단 및 치료에 대한 의식이 높아짐에 따라 가장 높은 성장률을 나타낼 것으로 예측됩니다. 의료 인프라의 진보와 고령화도 시장 확대에 기여하고 있습니다.
예측 기간 동안 아시아태평양이 가장 큰 시장 점유율을 차지할 것으로 예측됩니다. 전체적으로 환자의 결과를 개선하고 있습니다. 또한 정부의 지원과 헬스 케어 인프라의 확대가 시장 침투를 가속화하고, 구명을 위한 혈전 용해 요법을 보다 친숙하게 하고, 궁극적으로는 공중 보건의 향상과 지역의 의약품 상황의 강화에 기여하고 있습니다.
예측 기간 동안 북미는 혈전 용해 요법의 인지도 향상으로 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 노인 인구 증가와 낮은 침습 치료에 대한 수요는 우로키나제를 기반으로 한 치료의 보급을 촉진합니다.
According to Stratistics MRC, the Global Urokinase Market is accounted for $2.08 billion in 2025 and is expected to reach $3.50 billion by 2032 growing at a CAGR of 7.7% during the forecast period. Urokinase is a thrombolytic enzyme used medically to dissolve blood clots in the body. It is a serine protease originally derived from human urine, but now commonly produced using recombinant DNA technology. Urokinase works by converting plasminogen to plasmin, an enzyme that breaks down fibrin, the primary protein component of blood clots. It is primarily used to treat conditions such as pulmonary embolism, deep vein thrombosis, and catheter blockages. As a fibrinolytic agent, urokinase plays a vital role in restoring blood flow in occluded vessels, making it a critical therapeutic option in emergency and interventional medicine.
According to 2024 article by British Heart Foundation, 7.6 million people are living in with heart and circulatory disease in UK.
Rising Prevalence of Thrombotic Disorders
The growing incidence of thrombotic disorders is propelling the urokinase market due to the heightened need for thrombolytic treatments. The enzyme urokinase, which is employed to break down blood clots, plays a vital role in the treatment of conditions like pulmonary embolism, deep vein thrombosis, and acute myocardial infarction. As the global prevalence of these disorders rises, particularly among aging populations, the demand for effective clot-dissolving treatments is increasing. This trend is benefiting the urokinase market and spurring further developments in its production and application.
High Treatment Costs
High treatment costs significantly hinder the growth of the urokinase market by limiting accessibility for patients and healthcare providers, particularly in low- and middle-income regions. These elevated expenses reduce the adoption of urokinase-based therapies, as more affordable alternatives are sought. Additionally, high costs strain healthcare budgets, discourage insurance coverage, and restrict widespread clinical use, ultimately slowing market expansion and impeding innovation in thrombolytic treatments.
Technological Advancements in Drug Delivery
Technological advancements in drug delivery systems have significantly impacted the Urokinase market by enhancing its therapeutic efficacy and precision. Innovations such as targeted delivery mechanisms and nanoparticle-based formulations ensure better bioavailability and reduced side effects. These advancements improve the drug's ability to target specific sites, optimizing the treatment of conditions like blood clots and heart attacks. Additionally, controlled release technologies and personalized drug delivery systems contribute to improved patient outcomes, driving demand and growth within the Urokinase market.
Risk of Bleeding Complications
The risk of bleeding complications significantly hinders the growth of the urokinase market. Urokinase, a thrombolytic agent, carries a high potential for causing internal bleeding, particularly in patients with underlying conditions or on anticoagulants. This safety concern limits its widespread adoption among healthcare providers, prompting cautious prescription practices. Additionally, regulatory restrictions and the availability of safer alternatives further restrain market expansion, negatively impacting demand and overall market performance.
Covid-19 Impact
The COVID-19 pandemic significantly disrupted the urokinase market due to delays in elective surgeries, reduced hospital admissions, and supply chain interruptions. Demand for non-COVID-related therapies, including thrombolytic agents like urokinase, declined during the peak of the pandemic. However, as healthcare systems stabilized and surgical procedures resumed, the market began recovering. Additionally, increased awareness of thrombotic complications in COVID-19 patients indirectly supported demand for anticoagulant and thrombolytic therapies.
The urokinase solution segment is expected to be the largest during the forecast period
The urokinase solution segment is expected to account for the largest market share during the forecast period because Urokinase solutions, particularly in intravenous and local delivery forms, are gaining preference due to their ability to rapidly dissolve blood clots, improving patient outcomes in conditions like pulmonary embolism and deep vein thrombosis. The growing adoption of urokinase solutions in hospitals and healthcare facilities, combined with ongoing research, is further fueling the segment's positive impact on market expansion.
The deep vein thrombosis segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the deep vein thrombosis segment is predicted to witness the highest growth rate, due to the rising incidence of thrombotic disorders and increased awareness of early diagnosis and treatment. Urokinase, a thrombolytic agent, is widely used to dissolve blood clots in DVT patients, leading to its growing demand. Advancements in healthcare infrastructure and an aging population further contribute to market expansion. This trend positions DVT as a key driver fueling sustained growth and innovation in the urokinase market.
During the forecast period, the Asia Pacific region is expected to hold the largest market share due to rising cardiovascular cases, increased awareness, and improved access to advanced therapies are driving demand. This growth is fostering innovation, encouraging investments, and improving patient outcomes across developing nations. Additionally, government support and expanding healthcare infrastructure are accelerating market penetration, making life-saving thrombolytic therapies more accessible, ultimately contributing to better public health and a stronger regional pharmaceutical landscape.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to increasing awareness of thrombolytic therapies. Advancements in healthcare infrastructure, strong presence of key pharmaceutical players, and supportive regulatory frameworks further fuel market expansion. The growing geriatric population and demand for minimally invasive procedures enhance the uptake of urokinase-based treatments. Collectively, these factors are significantly improving patient outcomes and driving the regional market's growth and innovation.
Key players in the market
Some of the key players profiled in the Urokinase Market include Syner-Med Ltd., Microbix Biosystems Inc., Wuxi Green Pharmaceutical Co., Ltd., Jiangxi Haoran Bio-Pharma Co., Ltd., Medicure Inc., Lee's Pharmaceutical Holdings Ltd., Taj Pharmaceuticals Limited, Jiangsu Techpool Bio-Pharma Co., Ltd., Guangzhou Recomgen Biotech Co., Ltd., LGM Pharma, ScienCell Research Laboratories, Inc., BioVision, Inc., Abbott Laboratories, Enzo Life Sciences, Inc., Molecular Innovations, Inc., Prospec-Tany Technogene Ltd., Wuhan YZY Biopharma Co., Ltd., GenScript Biotech Corporation and Chymotech AS.
In August 2024, Abbott and Medtronic announced a significant global partnership, to integrate Abbott's FreeStyle Libre continuous glucose monitoring (CGM) technology with Medtronic's insulin delivery systems. This collaboration aims to enhance diabetes management by enabling automatic insulin adjustments based on real-time glucose data.
In June 2024, Abbott has partnered with the National Association of Community Health Centers (NACHC) to improve access to nutritious food and health services. The collaboration aims to enhance healthcare delivery and address the growing health challenges related to nutrition in underserved communities.